A Phase 2 interventional study of Enoxaparin and BIBR 1048 in Venous Thromboembolism, sponsored by Boehringer Ingelheim. Completed at 59 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-19.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.
Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 3rd largest by enrollment, is one of 2 that started in 2002, is one of 7 in phase 2, and was the 7th registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,973 is above the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 148 across the 17 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 6 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
17 studies in Venous Thromboembolism by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 15 finished, 13 (87%) have results posted.
Among the 17 studies in Venous Thromboembolism by Boehringer Ingelheim, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2002, is one of 7 in phase 2, and was the 8th registered.
Boehringer Ingelheim’s Venous Thromboembolism studies by the year they started, since 2000.
1 of the studies testing dabigatran in Venous Thromboembolism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735639Imperial College LondonTHRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing dabigatran in Venous Thromboembolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 17 in Venous Thromboembolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to establish the dose-response relationship with regard to efficacy and safety of BIBR 1048 (50 mg bis in die(b.i.d), 150 mg b.i.d, 225 mg b.i.d. and 300 mg quaque die(q.d) ) in preventing venous thromboembolism(VTE) in patients undergoing primary elective total hip and knee replacement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
Drug: BIBR 1048
BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
Drug: BIBR 1048
BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
Drug: BIBR 1048
BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
Drug: BIBR 1048
placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period
Drug: Enoxaparin
Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
300 mg q.d BIBR 1048 capsule for 5-10 treatment period
Number of Participants With Venous Thromboembolic (VTE) Events
Deep vein thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or PE confirmed by objective testing
Time frame: Treatment period (up to day 8+/-2 days visit)
Number of Participants With Major Bleeding Events (MBE)
Time frame: From approximately 14 days prior to surgery to 4-6 weeks post surgery
Number of Participants With VTE Events and All Cause Mortality
Deep venous thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or Pulmonary Embolism (PE) confirmed by objective testing and all deaths.
Time frame: Treatment period (up to day 8+/-2 days visit)
Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality
Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period or PE confirmed by objective testing plus VTE related mortality
Time frame: Treatment period (up to day 10)
Number of Participants With Proximal DVT
Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period
Time frame: Treatment period (up to day 8+/-2 days visit)
Volume of Blood Loss
Volume of blood loss was to be analysed using an analysis of variance (ANOVA), which included treatment and centre.
Time frame: Day 1 (Day of surgery)
Rate of Transfusions Due to Bleedings
Percentage of patients requiring transfusions due to bleeding .Rate of need of transfusion were to be analysed using a logistic regression with treatment and centre.
Time frame: Day 1 (Day of surgery)
Number of Participants With Clinically Significant, Minor or Any Bleeding Events
Number of participants with Clinically Significant, minor or any bleeding events. Clinically significant bleeding events are defined as * Spontaneous skin haematoma larger than \>25 cm² * Wound haematoma \>100 cm² * Spontaneous nose bleed \>5 minutes * Macroscopic haematurea, either spontaneous or lasting more than 24 hours if associated with an intervention * Spontaneous rectal bleeding (more than spot on toilet paper) * Gingival bleeding \>5 minutes * Any other bleeding event considered as clinically significant by the investigator All other bleeding events that did not fulfil the criteria of MBE or clinically significant bleeding event were classified as minor bleeding events.
Time frame: Treatment period (up to day 8+/-2 days visit)
Laboratory Analyses
Number of patients with possible clinically significant abnormalities, i.e. with values out of normal range. Normal ranges are defined as: Haematocrit \[%\]: (0.35-0.45) for women and (0.39-0.51) for men Haemoglobin \[g/dL\]: (11.6-15.4) for women and (13.2-17.3) for men White Blood Cell count \[10\^9/L\]: (4-10.3) for women and (3.9-10.3) for men Platelets \[10\^9/L\]: (145-420) for women and men Sodium \[mmol/L\]: (135-146) for women and men Potassium \[mmol/L\]: (3.5-5) for women and men Aspartate aminotransferase (AST) \[U/L\]: (11-37) for women and (11-39) for men Alanine aminotransferase (ALT) \[U/L\]: (8-43) for women and (8-45) for men Alkaline Phosphatase \[U/L\]: (36-118) for women and (35-123) for men Creatinine \[mg/dL\]: (0.57-1.06)for women and (0.72-1.3) for men Bilirubin, total \[mg/dL\]: (0.22-1.28) for women and men Uric acid \[mg/dL\]: (2.4-6.47) for women and men
Time frame: Screening to end of treatment
Plasma Concentration (Cmax) of Dabigatran
Maximum plasma concentration of Dabigatran (at steady-state) and Pre-dose plasma concentrations at steady state. Cmax represents the maximum concentration of Dabigatran in plasma. Cmax,ss represents the maximum concentration of Dabigatran in plasma at steady state. Cpre,ss represents pre-dose concentration of Dabigatran in plasma at steady state
Time frame: Day 1 to end of treatment
Area Under the Plasma Concentration-time Curve During a Dosing Interval
Area under the plasma concentration-time curve during a dosing interval (at steady-state). The AUC0-12h (for b.i.d. treatment regimens) and AUC0-24h (300 mg q.d.) after the first dose on day of surgery calculated by extrapolation using the elimination rate constant, reported only if the extrapolated fraction of AUC was less than 30 % of the total AUC.
Time frame: up to day 8+/-2 days visit
There were 1973 patients enrolled/randomised in this trial but only 1949 started treatment
| Milestone | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Started | 389 | 390 | 393 | 385 | 392 |
| Completed | 351 | 334 | 355 | 333 | 361 |
| Not completed | 38 | 56 | 38 | 52 | 31 |
| Withdrew: Adverse event | 13 | 31 | 18 | 23 | 14 |
| Withdrew: Protocol violation | 6 | 8 | 6 | 7 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 7 | 7 | 11 | 6 |
| Withdrew: Other | 13 | 10 | 7 | 10 | 7 |
Deep vein thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or PE confirmed by objective testing
| participants | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Number of Participants With Venous Thromboembolic (VTE) Events | 86 | 49 | 39 | 47 | 72 |
Deep venous thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or Pulmonary Embolism (PE) confirmed by objective testing and all deaths.
| participants | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Number of Participants With VTE Events and All Cause Mortality | 86 | 49 | 39 | 47 | 72 |
Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period or PE confirmed by objective testing plus VTE related mortality
| participants | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality | 15 | 11 | 5 | 6 | 17 |
Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period
| participants | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Number of Participants With Proximal DVT | 15 | 9 | 5 | 6 | 17 |
| participants | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Number of Participants With Major Bleeding Events (MBE) | 1 | 16 | 15 | 18 | 8 |
Volume of blood loss was to be analysed using an analysis of variance (ANOVA), which included treatment and centre.
| ml | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Volume of Blood Loss | 523.3 ± 845.8 | 1538.4 ± 1474.5 | 631.4 ± 720.9 | 910.3 ± 918.3 | 945.5 ± 651.3 |
Percentage of patients requiring transfusions due to bleeding .Rate of need of transfusion were to be analysed using a logistic regression with treatment and centre.
| Percentage of patients | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Rate of Transfusions Due to Bleedings | 0.26 | 5.38 | 4.07 | 4.94 | 3.57 |
Number of participants with Clinically Significant, minor or any bleeding events. Clinically significant bleeding events are defined as * Spontaneous skin haematoma larger than \>25 cm² * Wound haematoma \>100 cm² * Spontaneous nose bleed \>5 minutes * Macroscopic haematurea, either spontaneous or lasting more than 24 hours if associated with an intervention * Spontaneous rectal bleeding (more than spot on toilet paper) * Gingival bleeding \>5 minutes * Any other bleeding event considered as clinically significant by the investigator All other bleeding events that did not fulfil the criteria of MBE or clinically significant bleeding event were classified as minor bleeding events.
| participants | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Clinically significant bleeding events | 9 | 16 | 20 | 19 | 10 |
| Minor bleeding events | 18 | 31 | 38 | 37 | 25 |
| Any bleeding events | 26 | 61 | 65 | 62 | 43 |
Number of patients with possible clinically significant abnormalities, i.e. with values out of normal range. Normal ranges are defined as: Haematocrit \[%\]: (0.35-0.45) for women and (0.39-0.51) for men Haemoglobin \[g/dL\]: (11.6-15.4) for women and (13.2-17.3) for men White Blood Cell count \[10\^9/L\]: (4-10.3) for women and (3.9-10.3) for men Platelets \[10\^9/L\]: (145-420) for women and men Sodium \[mmol/L\]: (135-146) for women and men Potassium \[mmol/L\]: (3.5-5) for women and men Aspartate aminotransferase (AST) \[U/L\]: (11-37) for women and (11-39) for men Alanine aminotransferase (ALT) \[U/L\]: (8-43) for women and (8-45) for men Alkaline Phosphatase \[U/L\]: (36-118) for women and (35-123) for men Creatinine \[mg/dL\]: (0.57-1.06)for women and (0.72-1.3) for men Bilirubin, total \[mg/dL\]: (0.22-1.28) for women and men Uric acid \[mg/dL\]: (2.4-6.47) for women and men
| participants | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Haematocrit decrease (N=325,324,339,320,340) | 16 | 15 | 14 | 14 | 22 |
| Haemoglobin decrease (N=325,324,339,320,340) | 122 | 129 | 148 | 129 | 142 |
| White blood cell ct. decr.(N=325,324,339,320,340) | 0 | 0 | 2 | 1 | 0 |
| Platelets decrease (N=325,324,339,320,340) | 0 | 0 | 0 | 0 | 1 |
| Platelets increase (N=325,324,339,320,340) | 0 | 1 | 1 | 0 | 0 |
| Sodium decrease (N=340,334,344,327,352) | 0 | 2 | 0 | 1 | 0 |
| Potassium decrease (N=340,334,344,326,352) | 0 | 0 | 1 | 0 | 2 |
| Potassium increase (N=340,334,344,326,352) | 0 | 2 | 1 | 2 | 1 |
| AST increase (N=340,334,344,327,352) | 1 | 0 | 2 | 3 | 9 |
| ALT increase (N=340,334,344,327,352) | 6 | 5 | 3 | 8 | 20 |
| Alkaline phosphatase incr. (N=340,334,344,327,352) | 1 | 2 | 0 | 0 | 3 |
| Creatinine increase (N=340,334,344,327,352) | 0 | 2 | 0 | 1 | 1 |
| Bilirubin, total increase (N=340,334,344,327,352) | 0 | 0 | 0 | 1 | 0 |
| Uric Acid increase (N=340,334,344,327,352) | 3 | 4 | 4 | 2 | 3 |
Maximum plasma concentration of Dabigatran (at steady-state) and Pre-dose plasma concentrations at steady state. Cmax represents the maximum concentration of Dabigatran in plasma. Cmax,ss represents the maximum concentration of Dabigatran in plasma at steady state. Cpre,ss represents pre-dose concentration of Dabigatran in plasma at steady state
| ng/mL | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Cmax (N=88, 83, 84, 96, 0) | 24.5 ± 115 | 60.5 ± 97.3 | 79.9 ± 94.7 | 132 ± 81.6 | — |
| Cmax at steady-state (N=87, 74, 79, 85, 0) | 48.0 ± 64.6 | 165 ± 63.6 | 257 ± 62.7 | 271 ± 75.2 | — |
| Cpre at steady-state | 19.6 ± 70.7 | 70.3 ± 87.3 | 113 ± 80.9 | 38.0 ± 85.9 | — |
Area under the plasma concentration-time curve during a dosing interval (at steady-state). The AUC0-12h (for b.i.d. treatment regimens) and AUC0-24h (300 mg q.d.) after the first dose on day of surgery calculated by extrapolation using the elimination rate constant, reported only if the extrapolated fraction of AUC was less than 30 % of the total AUC.
| ng*h/mL | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| AUC during a dosing interval (N=13,12,21,72,0) | 229 ± 88.1 | 636 ± 56.2 | 605 ± 91.6 | 1610 ± 82.5 | — |
| AUC during a dosing interval at steady-state | 350 ± 66.8 | 1250 ± 64.8 | 1910 ± 64.9 | 2450 ± 76.1 | — |
Collected over 14 days +/- 2 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BIBR 1048 50 mg Bid | — | 25/389 (6.4%) | 242/389 (62.2%) |
| BIBR 1048 150 mg Bid | — | 29/390 (7.4%) | 267/390 (68.5%) |
| BIBR 1048 225 mg Bid | — | 21/393 (5.3%) | 256/393 (65.1%) |
| BIBR 1048 300 mg qd | — | 33/385 (8.6%) | 267/385 (69.4%) |
| Enoxaparin 40 mg qd | — | 31/392 (7.9%) | 258/392 (65.8%) |
| Event | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| Venous thrombosis deep limbVascular disorders | 5/389 | 1/390 | 1/393 | 1/385 | 2/392 |
| Wound infection NECInfections and infestations | 1/389 | 1/390 | 3/393 | 3/385 | 3/392 |
| Joint dislocation NECInjury, poisoning and procedural complications | 0/389 | 3/390 | 0/393 | 3/385 | 1/392 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/389 | 0/390 | 2/393 | 3/385 | 1/392 |
| Pulmonary embolismVascular disorders | 1/389 | 3/390 | 0/393 | 0/385 | 0/392 |
| Deep venous thrombosis NOSVascular disorders | 1/389 | 0/390 | 0/393 | 1/385 | 3/392 |
| Rectal haemorrhageGastrointestinal disorders | 0/389 | 1/390 | 1/393 | 2/385 | 1/392 |
| PyrexiaGeneral disorders | 0/389 | 0/390 | 0/393 | 2/385 | 0/392 |
| Post-operative wound infectionInfections and infestations | 1/389 | 0/390 | 0/393 | 2/385 | 0/392 |
| Dislocation of joint prosthesisInjury, poisoning and procedural complications | 1/389 | 0/390 | 1/393 | 2/385 | 1/392 |
| Event | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 84/389 | 105/390 | 92/393 | 105/385 | 111/392 |
| Vomiting NOSGastrointestinal disorders | 76/389 | 77/390 | 75/393 | 76/385 | 66/392 |
| InsomniaPsychiatric disorders | 59/389 | 45/390 | 52/393 | 59/385 | 51/392 |
| ConstipationGastrointestinal disorders | 33/389 | 38/390 | 34/393 | 46/385 | 34/392 |
| PyrexiaGeneral disorders | 33/389 | 30/390 | 36/393 | 35/385 | 32/392 |
| Venous thrombosis deep limbVascular disorders | 33/389 | 12/390 | 13/393 | 12/385 | 16/392 |
| Anaemia NOSBlood and lymphatic system disorders | 23/389 | 26/390 | 27/393 | 22/385 | 18/392 |
| Hypotension NOSVascular disorders | 19/389 | 25/390 | 21/393 | 21/385 | 20/392 |
| Post procedural drainageInjury, poisoning and procedural complications | 12/389 | 16/390 | 23/393 | 18/385 | 8/392 |
| Wound secretionInjury, poisoning and procedural complications | 15/389 | 21/390 | 16/393 | 17/385 | 6/392 |
| Age, Customized(years) | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd | Total |
|---|---|---|---|---|---|---|
| Mean | 66.07 ± 10.23 | 65.86 ± 10.77 | 65.87 ± 10.63 | 66.47 ± 10.37 | 65.03 ± 11.03 | 65.86 ± 10.61 |
| Sex: Female, Male(Participants) | BIBR 1048 50 mg Bid | BIBR 1048 150 mg Bid | BIBR 1048 225 mg Bid | BIBR 1048 300 mg qd | Enoxaparin 40 mg qd | Total |
|---|---|---|---|---|---|---|
| Female | 223 | 252 | 229 | 246 | 241 | 1191 |
| Male | 166 | 138 | 164 | 139 | 151 | 758 |
The record gives a start of Nov 2002 and a primary completion of Aug 2003. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 7 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran